Inspiration's US filing for haemophilia B product triggers $35m milestone from Ipsen
This article was originally published in Scrip
Executive Summary
Inspiration Biopharmaceuticals has submitted a biologics license application (BLA) to the US FDA for the approval of IB1001, an intravenous recombinant factor IX for the treatment and prevention of bleeding in haemophilia B.